La Agencia Europea de Medicamentos (EMA) ha aprobado una opción adicional de administración subcutánea de TAKHZYRO® (lanadelumab) para pacientes de 12 años o más con ataques recurrentes de angioedema hereditario (AEH) La solución inyectable TAKHZYRO en pluma precargada de 2 ml ya está…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.